Pharma

Your Article Summary

See Latest Articles

Fda accepts drug application for miconazole lauriad to treat oropharyngeal candidiasis
Par Pharmaceutical, 08/20/09

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. , announced that the U.S. Food and Drug Administration has accepted the new drug application for miconazole Lauriad mucoadhesive buccal tablets to treat oropharyngeal candidiasis. Miconazole MBT delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once–daily dosing of the active ingredient at the site of infection.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals